GlassScriptPhysician profile
Cassandra J Mclaughlin
NPI 1497913594
$535.14
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.78 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.13 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.45 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.63 | 2022 | |
| Cranial Technologies, INC | $26.06 | 2021 | |
| Biotronik INC. | $24.77 | 2021 | |
| Gilead Sciences, INC. | $18.62 | 2021 | |
| Novo Nordisk INC | $16.48 | 2022 | |
| Lilly USA, LLC | $16.21 | 2021 | |
| Boston Scientific Corporation | $14.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.70 | 2021 | |
| Travere Therapeutics, INC. | $1.18 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.